PsilodexMedication × psilocybin
Your list , 0 items
Sources

Where every line comes from.

Every record and every pharmacology property cites a public source. State rules link to the official text and show when they were last checked. Data as of 2026-11-09.

145Papers
8Reference works
147Labels and databases
3State rules

01 State rules

Official text governs · All state materials
COFinal · rule text checked 2026-10-24

Colorado Natural Medicine Program (Office of Natural Medicine Licensure, Division of Professions and Occupations).
4 CCR 755-1.

Official text →

Applies to every participant regardless of medication: 2.2(A)(4), 6.15(C)(2)(c)(2), 6.16(F)(1), 6.17(C), 2.2(A)(9).

ORFinal · rule text checked 2026-10-24

Oregon Psilocybin Services (Oregon Health Authority).
OAR 333-333-5050 and the Client Information Form.

Official text →

Applies to every participant regardless of medication: 333-333-5050(3)(b), 333-333-5050(3)(d).

NMPending · rule text checked 2026-10-24

New Mexico Medical Psilocybin Program (Department of Health).
Proposed 7.35.3 NMAC.

Official text →

02 Product labels

560Records linked to an FDA label

US prescribing information or OTC Drug Facts, via DailyMed. Each record links its own label; flags and half-lives are checked against the label text.

21Records using non-US product information

For medications not sold in the US: the EU Summary of Product Characteristics or equivalent, linked per record.

03 Reference works

Cited by page
Bazire S. Psychotropic Drug Directory 2018. Lloyd-Reinhold Publications, 2018. ISBN 978-0-9569156-4-1
Brunton LL, Knollmann BC (eds). Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed. McGraw Hill, 2023. ISBN 978-1-264-25807-9
Preston CL (ed). Stockley’s Drug Interactions, 11th ed. Pharmaceutical Press, 2016. ISBN 978-0-85711-270-5
Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry, 15th ed. Wiley, 2025. ISBN 978-1-394-23876-7
AHFS Drug Information (American Society of Health-System Pharmacists), professional monograph via Drugs.com (per-drug link)
Other public reference page (per-entry link)
StatPearls (NCBI Bookshelf), drug monograph Indications section (per-drug link)
Vicente LLP. DEA places three kratom-related substances in Schedule I as 7-OH scheduling remains pending. September 9, 2026.

04 Government and databases

Centers for Disease Control and Prevention. Medetomidine in the U.S. illegal fentanyl supply increasing risk for overdose and severe withdrawal syndrome. Health Alert Network HAN-00527, April 2, 2026.
Colorado Session Laws 2023, ch. 249 (SB23-290), C.R.S. 12-170-104(12) definition of "natural medicine".
DEA Diversion Control Division. Medetomidine (including dexmedetomidine) fact sheet, March 2026.
Drug Enforcement Administration. Schedules of controlled substances: temporary placement of 7-hydroxymitragynine above a specified threshold in Schedule I (notice of intent). Federal Register, July 6, 2026 (FR Doc. 2026-13580).
European Union Drugs Agency (EUDA). Heroin drug profile. https://www.euda.europa.eu/publications/drug-profiles/heroin_en (accessed 2026-10-03)
FDA Pharmacy Compounding Advisory Committee briefing document: ibutamoren (October 2024).
FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (updated 2026-04-22).
FDA. Sage Therapeutics, Inc.; Withdrawal of Approval of a New Drug Application for ZULRESSO (brexanolone). Federal Register, March 14, 2025 (2025-04101).
National Institute on Drug Abuse (NIDA), NIH. Research-topic pages (per-entry link).
NIH LiverTox (NCBI Bookshelf) entry (per-entry link)
NIH National Center for Complementary and Integrative Health fact sheet (per-entry link)
NIH Office of Dietary Supplements fact sheet (per-entry link)
US Drug Enforcement Administration. 2025 National Drug Threat Assessment. May 2025.
US Drug Enforcement Administration. Drug Fact Sheets (per-entry link).
US Drug Enforcement Administration. State and Territory Report on Enduring and Emerging Threats (STREET): Nitazenes — an emerging threat of a diverse group of synthetic opioids (STR-002-25). September 2025.
US FDA consumer or public-health page (per-entry link)
US FDA. Amending OTC Monograph M012 (proposed order OTC000036). Federal Register, 8 Nov 2024 (doc 2024-25910)
US FDA. Drug Shortages database: current and resolved drug shortages and discontinuations reported to FDA (per-ingredient link).
US Food and Drug Administration. Concentrated 7-OH opioid products (FDA report to HHS supporting scheduling recommendation), July 2025.
World Health Organization Expert Committee on Drug Dependence (ECDD) review documents (per-entry link)
NIMH Psychoactive Drug Screening Program (PDSP) Ki Database, University of North Carolina. Roth BL et al. (per-entry query link; primary references in note)

05 Papers

145 · by first author
Abukahok N, Fitzgerald ND, Palamar JJ. An update on the epidemiology of tusi ("pink cocaine"). Curr Addict Rep 2025;12. doi:10.1007/s40429-025-00706-y
AJMC. FDA panel backs 6 peptides for compounding (PCAC, July 2026). link
Avula B, Wang YH, Rumalla CS, Smillie TJ, Khan IA. Simultaneous determination of alkaloids and flavonoids from aerial parts of Passiflora species and dietary supplements using UPLC-UV-MS and HPTLC. Nat Prod Commun 2012;7(9):1177-80. link
Bäckberg M, Beck O, Helander A. Phencyclidine analog use in Sweden—intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. Clin Toxicol (Phila) 2015;53(9):856–864. doi:10.3109/15563650.2015.1079325
Baggott MJ, Garrison KJ, Coyle JR, et al. Effects of the psychedelic amphetamine MDA (3,4-methylenedioxyamphetamine) in healthy volunteers. J Psychoactive Drugs 2019;51(2):108–117. doi:10.1080/02791072.2019.1593560
Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4(5):281–297. doi:10.2165/00129784-200404050-00002
Balíková M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci Int 2005;153(1):85–91. doi:10.1016/j.forsciint.2005.04.022
Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303. doi:10.1080/02791072.2024.2368617
Bazydlo LAL, Larkey NE. Testing strategies and the emergence of designer benzodiazepines. Clin Lab Med 2025;45(2):305–314. doi:10.1016/j.cll.2025.01.013
Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment. Clin Pharmacol Ther 2022;111(4):886–895. doi:10.1002/cpt.2487
Becker AM, Humbert-Droz M, Mueller L, et al. Acute effects and pharmacokinetics of LSD after paroxetine or placebo pre-administration in a randomized, double-blind, cross-over phase I trial. Clin Pharmacol Ther 2025;117(6):1784–1792. doi:10.1002/cpt.3618
Berar A, Allain JS, Allard S, et al. Intoxication with 3-MeO-PCP alone: a case report and literature review. Medicine (Baltimore) 2019;98(52):e18295. doi:10.1097/MD.0000000000018295
Berquist MD, Gannon BM, Honeywell KM, et al. Interoceptive effects of N-substituted lysergamides in rats: role of agonist affinity at 5-hydroxytryptamine receptors and in vivo metabolism to lysergic acid diethylamide. J Pharmacol Exp Ther 2026:104988. doi:10.1016/j.jpet.2026.104988
Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996;14:425–436. doi:10.1016/0893-133X(95)00145-4
Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229–233. doi:10.1016/0166-4328(96)00102-7
Bowen JS, Davis GB, Kearney TE, Bardin J. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion. JAMA 1983;249(11):1477–1479. PMID 6827726. link
Brandt SD, Kavanagh PV, Westphal F, et al. Return of the lysergamides. Part III: analytical characterization of N-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). Drug Test Anal 2017;9(10):1641–1649. doi:10.1002/dta.2196
Brandt SD, Walters HM, Partilla JS, et al. The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats. Psychopharmacology (Berl) 2020;237(12):3703–3714. doi:10.1007/s00213-020-05648-z
Chen J, Wang Z, Yong CY, et al. Elucidating the Phase I metabolism of psilocin in vitro. Arch Toxicol 2025;99(3):1085–1094. doi:10.1007/s00204-024-03952-7
Chisamore N, Kaczmarek ES, Doyle Z, et al. Comparing antidepressant effects of psilocybin-assisted psychotherapy in individuals unmedicated at screening versus individuals discontinuing medications. Can J Psychiatry 2025;70(10):759–767. doi:10.1177/07067437251328316
Chu NS. Effects of betel chewing on the central and autonomic nervous systems. J Biomed Sci 2001;8(3):229–236. doi:10.1007/BF02256596
Cilia R, Laguna J, Cassani E, et al. Daily intake of Mucuna pruriens in advanced Parkinson's disease: a 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord 2018;49:60-66. doi:10.1016/j.parkreldis.2018.01.014
Cilia R, Laguna J, Cassani E, et al. Mucuna pruriens in Parkinson disease: a double-blind, randomized, controlled, crossover study. Neurology 2017;89(5):432-438. doi:10.1212/WNL.0000000000004175
Cohen PA, Travis JC, Keizers PHJ, Deuster P, Venhuis BJ. Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA). Clin Toxicol (Phila) 2018;56(6):421-426. doi:10.1080/15563650.2017.1398328
Copeland CS, Hudson S, Treble R, Hamnett HJ. The first fatal intoxication with 3-MeO-PCP in the UK and a review of the literature. J Anal Toxicol 2022;46(5):461–470. doi:10.1093/jat/bkac015
Correia MS, Gonzaga MJ, Temple C, Gerona RR. Quantitative analysis of recreational psychoactive mushroom gummies in Portland, Oregon. Clin Toxicol (Phila) 2025;63(4):261-266. doi:10.1080/15563650.2025.2450240
Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab 2022;34(9):1234–1247. doi:10.1016/j.cmet.2022.07.013
Da Broi U, Colatutto A, Sala P, Desinan L. Medico legal investigations into sudden sniffing deaths linked with trichloroethylene. J Forensic Leg Med 2015;34:81–87. doi:10.1016/j.jflm.2015.05.016
Dahan A, Franko TS, Carroll JW, et al. Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids. Front Public Health 2024;12:1346109. doi:10.3389/fpubh.2024.1346109
de Sousa Fernandes Perna EB, Theunissen EL, Dolder PC, et al. Safety profile and neurocognitive function following acute 4-fluoroamphetamine (4-FA) administration in humans. Front Pharmacol 2018;9:713. doi:10.3389/fphar.2018.00713
Do A, Michaud V, Stephan JF, et al. Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report. Front Psychiatry 2024;15:1394962. doi:10.3389/fpsyt.2024.1394962
Dosoky NS, Shah SA, Dawson JT, et al. Chemical composition, market survey, and safety assessment of blue lotus (Nymphaea caerulea Savigny) extracts. Molecules 2023;28(20):7014. doi:10.3390/molecules28207014
Edwards C, Van Gerpen S, Anand V. New-onset seizures in an adolescent following use of LSD while on low-dose lithium therapy: a case study. S D Med 2024;77(1):31–35. link
Eghdami S, Eissazade N, Heidari Mokarar M, et al. The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials. Front Psychiatry 2024;15:1421150. doi:10.3389/fpsyt.2024.1421150
El Balkhi S, Coutaz-Fluck C, Moreau F, Paraf F, Gaulier JM. Is it worth carrying out determination of N-butane in postmortem samples? A case report and a comprehensive review of the literature. Int J Legal Med 2016;130(5):1223–1229. doi:10.1007/s00414-015-1260-9
Erritzoe D, Barba T, Spriggs MJ, et al. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. J Psychopharmacol 2024;38(5):458–470. doi:10.1177/02698811241237870
Falchi-Carvalho M, Palhano-Fontes F, Wießner I, et al. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology 2025;50(6):895–903. doi:10.1038/s41386-025-02091-6
Fisher AA, Purcell P, Le Couteur DG. Toxicity of Passiflora incarnata L. J Toxicol Clin Toxicol 2000;38(1):63-6. doi:10.1081/clt-100100919
Gerostamoulos D, Glowacki L, Pricone M, et al. Fatal intoxications from a combination of 4-fluoroamphetamine and 25C-NBOMe. J Anal Toxicol 2023;47(2):191–196. doi:10.1093/jat/bkac059
Glatfelter GC, Pottie E, Partilla JS, et al. Structure–activity relationships for psilocybin, baeocystin, aeruginascin, and related analogues to produce pharmacological effects in mice. ACS Pharmacol Transl Sci 2022;5(11):1181–1196. doi:10.1021/acsptsci.2c00177
Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999;16(9):1412–1416. doi:10.1023/a:1018955126402
Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 2023;48(10):1492–1499. doi:10.1038/s41386-023-01648-7
Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev 1994;19(2):180-222. doi:10.1016/0165-0173(94)90011-6
Gresnigt FMJ, Snik A, Franssen EJF, et al. 4-Fluoroamphetamine (4-FA) intoxication results in exaggerated blood pressure effects compared to MDMA and amphetamine: a retrospective analysis. J Am Coll Emerg Physicians Open 2022;3(5):e12813. doi:10.1002/emp2.12813
Grimley Evans J, Malouf R, Huppert F, van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst Rev 2006;(4):CD006221. doi:10.1002/14651858.CD006221
Grumann C, Henkel K, Brandt SD, et al. Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration. Drug Test Anal 2020;12(8):1144–1153. doi:10.1002/dta.2821
Gukasyan N, Griffiths RR, Yaden DB, et al. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. J Psychopharmacol 2023;37:707–716. doi:10.1177/02698811231179910
Guo J, Chen H, Zhang X, et al. The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Oxid Med Cell Longev 2021;2021:2074610. doi:10.1155/2021/2074610
Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol 2012;68(2):213-7. doi:10.1007/s00228-011-1108-2
Hajek T, Munthe S, Licht RW. Lithium orotate: distinct compound or simply Li(+) after administration? Br J Psychiatry 2026. doi:10.1192/bjp.2026.10699
Halberstadt AL, Chatha M, Klein AK, et al. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). Neuropharmacology 2020;172:107856. doi:10.1016/j.neuropharm.2019.107856
Halberstadt AL. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine. Pharmacol Biochem Behav 2016;143:1–10. doi:10.1016/j.pbb.2016.01.005
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. doi:10.1177/02698811231211219
Hammoud F, Ismail A, Zaher R, El Majzoub R, Abou-Abbas L. Mucuna pruriens treatment for Parkinson disease: a systematic review of clinical trials. Parkinsons Dis 2025;2025:1319419. doi:10.1155/padi/1319419
Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006;6:6. doi:10.1186/1471-2210-6-6
Harvey AL, Young LC, Viljoen AM, Gericke NP. Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids. J Ethnopharmacol 2011;137(3):1124-9. doi:10.1016/j.jep.2011.07.035
Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009;6:31. doi:10.1186/1743-7075-6-31
Hill SL, Harbon SCD, Coulson J, et al. Methoxetamine toxicity reported to the National Poisons Information Service: clinical characteristics and patterns of enquiries. Emerg Med J 2014;31(1):45–47. doi:10.1136/emermed-2012-202251
Huo S, London K, Murphy L, et al. Notes from the field: suspected medetomidine withdrawal syndrome among fentanyl-exposed patients — Philadelphia, Pennsylvania, September 2024–January 2025. MMWR 2025;74:266–268. doi:10.15585/mmwr.mm7415a2
Isbell H, Wolbach AB, Wikler A, Miner EJ. Cross tolerance between LSD and psilocybin. Psychopharmacologia 1961;2:147–159. doi:10.1007/BF00407974
Jamshidi N, Cohen MM. The clinical efficacy and safety of tulsi in humans: a systematic review of the literature. Evid Based Complement Alternat Med 2017;2017:9217567. doi:10.1155/2017/9217567
Jansson R, Lindström B, Dahlberg PA. Pharmacokinetic properties and bioavailability of methimazole. Clin Pharmacokinet 1985;10(5):443–450. doi:10.2165/00003088-198510050-00006
Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148(10):1301–1308. doi:10.1176/ajp.148.10.1301
Jevtović-Todorović V, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 1998;4(4):460–463. doi:10.1038/nm0498-460
Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008;22(6):603–620. doi:10.1177/0269881108093587
Jones NT, Wagner L, Hahn MCP, Scarlett CO, Wenthur CJ. In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin. Front Psychiatry 2024;14:1303365. doi:10.3389/fpsyt.2023.1303365
Jouney EA. Phenibut (beta-phenyl-gamma-aminobutyric acid): an easily obtainable 'dietary supplement' with propensities for physical dependence and addiction. Curr Psychiatry Rep 2019;21(4):23. doi:10.1007/s11920-019-1009-0
Keeler MH. Chlorpromazine antagonism of psilocybin effect. Int J Neuropsychiatry 1967;3:66–71.
Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction 2022;117(1):118–128. doi:10.1111/add.15448
Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules 2015;20(2):2208–2228. doi:10.3390/molecules20022208
Kuc J, Kettner H, Rosas F, et al. Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. Psychopharmacology (Berl) 2022;239(5):1425–1440. doi:10.1007/s00213-021-05999-1
Kuypers KPC, De Sousa Fernandes Perna EB, Theunissen EL, et al. A first-in-man study with 4-fluoroamphetamine demonstrates it produces a mild psychedelic state. J Psychoactive Drugs 2019;51(3):225–235. doi:10.1080/02791072.2019.1569286
Kwon O, Kim Y, Paek JH, et al. Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: a case report. Medicine (Baltimore) 2022;101(10):e28997. doi:10.1097/MD.0000000000028997
Lake S, Lucas P. Co-use of psychedelics with other substances: findings from the global psychedelic survey. J Psychopharmacol 2025;39(5):453–462. doi:10.1177/02698811241292956
Lee MS, Lee HW, You S, Ha KT. The use of maca (Lepidium meyenii) to improve semen quality: a systematic review. Maturitas 2016;92:64-69. doi:10.1016/j.maturitas.2016.07.013
Leisegang K, Finelli R, Sikka SC, Panner Selvam MK. Eurycoma longifolia (Jack) improves serum total testosterone in men: a systematic review and meta-analysis of clinical trials. Medicina (Kaunas) 2022;58(8):1047. doi:10.3390/medicina58081047
Liu S, O'Donnell J, Gladden RM, McGlone L, Chowdhury F. Trends in nonfatal and fatal overdoses involving benzodiazepines — 38 states and the District of Columbia, 2019–2020. MMWR 2021;70(34):1136–1141. doi:10.15585/mmwr.mm7034a2
Luethi D, Walter M, Zhou X, et al. Para-halogenation affects monoamine transporter inhibition properties and hepatocellular toxicity of amphetamines and methcathinones. Front Pharmacol 2019;10:438. doi:10.3389/fphar.2019.00438
Manevski N, Kurkela M, Höglund C, et al. Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metab Dispos 2010;38(3):386–395. doi:10.1124/dmd.109.031138
Martin R, Buffenstein I, Cho D, Kiyokawa M. Toxidrome of an easily obtainable nootropic: a case report of phenibut intoxication and withdrawal delirium. J Clin Psychopharmacol 2023;43(6):507-510. doi:10.1097/JCP.0000000000001759
Marwood L, Croal M, Mistry S, et al. The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. J Psychiatr Res 2024;180:198–203. doi:10.1016/j.jpsychires.2024.10.009
Mathews IM, Eastwood J, Lamport DJ, et al. Clinical efficacy and tolerability of lemon balm (Melissa officinalis L.) in psychological well-being: a review. Nutrients 2024;16(20):3545. doi:10.3390/nu16203545
McBride MC. Bufotenine: toward an understanding of possible psychoactive mechanisms. J Psychoactive Drugs 2000;32(3):321–331. doi:10.1080/02791072.2000.10400456
Mezaache S, Pochard L, Peyrière H, et al. Emerging new psychoactive ketamine analogues: patterns of use and health risks identified by the French Addictovigilance Network. Int J Drug Policy 2026;153:105326. doi:10.1016/j.drugpo.2026.105326
Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med 2010;16(7):753-9. doi:10.1089/acm.2009.0342
Moss MJ, Hendrickson RG. Toxicity of muscimol and ibotenic acid containing mushrooms reported to a regional poison control center from 2002-2016. Clin Toxicol (Phila) 2019;57(2):99-103. doi:10.1080/15563650.2018.1497169 doi:10.1080/15563650.2018.1497169
Mukai T, Kishi T, Matsuda Y, Iwata N. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol 2014;29(1):55-63. doi:10.1002/hup.2369
Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med 2008;149(9):601–611. doi:10.7326/0003-4819-149-9-200811040-00003
Nayak SM, Gukasyan N, Barrett FS, et al. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures. Pharmacopsychiatry 2021. doi:10.1055/a-1524-2794
Nicholas CR, Banks MI, Lennertz RC, et al. Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience. Transl Psychiatry 2024;14:372. doi:10.1038/s41398-024-03059-8
Nicholas CR, Horton DM, Malicki J, et al. Psilocybin for opioid use disorder in two adults stabilized on buprenorphine: a technical report on study modifications and preliminary findings. Psychedelic Med 2023;1(4):253–261. doi:10.1089/psymed.2023.0012
Ochi T, Sakamoto M, Minamida A, et al. Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423. Bioorg Med Chem Lett 2005;15:1055. doi:10.1016/j.bmcl.2004.12.028
Olatunji TL, Siebert F, Adetunji AE, et al. Sceletium tortuosum: a review on its phytochemistry, pharmacokinetics, biological and clinical activities. J Ethnopharmacol 2021;280:114476. doi:10.1016/j.jep.2021.114476
Ott J. Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J Psychoactive Drugs 2001;33(3):273–281. doi:10.1080/02791072.2001.10400574
Papaseit E, Farré M, Pérez-Mañá C, et al. Acute pharmacological effects of 2C-B in humans: an observational study. Front Pharmacol 2018;9:206. doi:10.3389/fphar.2018.00206
Pauzé DK, Brooks DE. Lithium toxicity from an Internet dietary supplement. J Med Toxicol 2007;3(2):61–62. doi:10.1007/BF03160910
Penzak SR, Bulloch M. Phenibut: review and pharmacologic approaches to treating withdrawal. J Clin Pharmacol 2024;64(6):652-671. doi:10.1002/jcph.2414
Pepe M, Di Nicola M, Cocciolillo F, et al. 3-Methoxy-phencyclidine induced psychotic disorder: a literature review and an 18F-FDG PET/CT case report. Pharmaceuticals (Basel) 2024;17(4):452. doi:10.3390/ph17040452
Piercey CJ, Hetelekides E, Karoly HC. Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado. J Cannabis Res 2024;6:29. doi:10.1186/s42238-024-00235-x
Poklis JL, Mulder HA, Halquist MS, et al. The blue lotus flower (Nymphea caerulea) resin used in a new type of electronic cigarette, the re-buildable dripping atomizer. J Psychoactive Drugs 2017;49(3):175-181. doi:10.1080/02791072.2017.1290304
Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol 2016;26:756–766. doi:10.1016/j.euroneuro.2016.01.005
Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012;8(1):33–42. doi:10.1007/s13181-011-0193-z
Reckweg J, Mason NL, van Leeuwen C, et al. A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-MeO-DMT formulation (GH001) in healthy volunteers. Front Pharmacol 2021;12:760671. doi:10.3389/fphar.2021.760671
Resnick O, Krus DM, Raskin M. LSD-25 action in normal subjects treated with a monoamine oxidase inhibitor. Life Sci 1964;3:1207–1214.
Riess S, Chèze M, Muckensturm A, et al. 2-Fluorodeschloroketamine consumption: about two deaths and a case of self-mutilation. J Anal Toxicol 2024;48(5):398–404. doi:10.1093/jat/bkae021
Roberts A, Korona-Bailey J, Mukhopadhyay S. Notes from the field: nitazene-related deaths — Tennessee, 2019–2021. MMWR 2022;71(37):1196–1197. doi:10.15585/mmwr.mm7137a5
Rosenblat JD, et al. Antidepressant effects of psilocybin in the absence of psychedelic effects. Am J Psychiatry 2023 (letter). doi:10.1176/appi.ajp.20220835
Roth BL, Gibbons S, Arunotayanun W, et al. The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 2013;8(3):e59334. doi:10.1371/journal.pone.0059334
Sakai K, Bradley ER, Zamaria JA, et al. Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms. Psychopharmacology 2024;241(8):1617–1630. doi:10.1007/s00213-024-06585-x
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. doi:10.1007/s00213-022-06083-y
Schifano F, Catalani V, Sharif S, et al. Benefits and harms of 'smart drugs' (nootropics) in healthy individuals. Drugs 2022;82(6):633-647. doi:10.1007/s40265-022-01701-7
Schifano F, Chiappini S, Miuli A, et al. New psychoactive substances (NPS) and serotonin syndrome onset: a systematic review. Exp Neurol 2021;339:113638. doi:10.1016/j.expneurol.2021.113638
Schimpf M, Ulmer T, Hiller H, Barbuto AF. Toxicity from blue lotus (Nymphaea caerulea) after ingestion or inhalation: a case series. Mil Med 2023;188(7-8):usab328. doi:10.1093/milmed/usab328
Shen HW, Jiang XL, Winter JC, Yu AM. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab 2010;11(8):659–666. doi:10.2174/138920010794233495
Siefried KJ, Freeman G, Roberts DM, et al. Inpatient GHB withdrawal management in an inner-city hospital in Sydney, Australia: a retrospective medical record review. Psychopharmacology (Berl) 2023;240(1):127–135. doi:10.1007/s00213-022-06283-6
Siervo M, Lara J, Ogbonmwan I, Mathers JC. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis. J Nutr 2013;143(6):818-26. doi:10.3945/jn.112.170233
Singhani V, et al. Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: a narrative expert review. Nutr Clin Pract 2026;41(5):1318–1333. doi:10.1002/ncp.70180
Sklerov J, Levine B, Moore KA, King T, Fowler D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol 2005;29(8):838–841. doi:10.1093/jat/29.8.838
Soh J, Raventhiran S, Lee JH, et al. The effect of glycine administration on the characteristics of physiological systems in human adults: a systematic review. Geroscience 2024;46(1):219-239. doi:10.1007/s11357-023-00970-8
Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004;32(6):587-94. doi:10.1124/dmd.32.6.587
Strassman RJ. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res 1996;73(1-2):121–124. doi:10.1016/0166-4328(96)00081-2
Sutherland MH, Nicholas CR, Lennertz RC, et al. Electrophysiological effects of psilocybin co-administered with midazolam. Transl Psychiatry 2026;16. doi:10.1038/s41398-026-03894-x
Tang MHY, Li TC, Lai CK, et al. Emergence of new psychoactive substance 2-fluorodeschloroketamine: toxicology and urinary analysis in a cluster of patients exposed to ketamine and multiple analogues. Forensic Sci Int 2020;312:110327. doi:10.1016/j.forsciint.2020.110327
Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025. doi:10.1177/02698811251368360
Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab 2006;91(3):799–805. doi:10.1210/jc.2005-1536
Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689. doi:10.3389/fphar.2024.1391689
Thornton S, Lisbon D, Lin T, Gerona R. Beyond ketamine and phencyclidine: analytically confirmed use of multiple novel arylcyclohexylamines. J Psychoactive Drugs 2017;49(4):289–293. doi:10.1080/02791072.2017.1333660
Thuy NHL, Tu VL, Thu LNA, et al. Pharmacological activities and safety of Ganoderma lucidum spores: a systematic review. Cureus 2023;15(9):e44574. doi:10.7759/cureus.44574
Toennes SW, Schneider D, Pogoda W, et al. Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion. Drug Test Anal 2019;11(7):1028–1034. doi:10.1002/dta.2595
Ulbricht C, Conquer J, Flanagan K, et al. An evidence-based systematic review of tongkat ali (Eurycoma longifolia) by the Natural Standard Research Collaboration. J Diet Suppl 2013;10(1):54-83. doi:10.3109/19390211.2012.761467
Uno T, Yasui-Furukori N. Effect of grapefruit juice in relation to human pharmacokinetic study. Curr Clin Pharmacol 2006;1(2):157–161. doi:10.2174/157488406776872550
Vallianou NG, Kounatidis DC, Dalamaga M, et al. Alpha-lipoic acid as a trigger of insulin autoimmune syndrome: current evidence, a case-based approach, diagnostic pitfalls, and practical management. Metabol Open 2026;31:100491. doi:10.1016/j.metop.2026.100491
van Amsterdam JGC, Nabben T, van den Brink W. Increasing recreational nitrous oxide use: should we worry? A narrative review. J Psychopharmacol 2022;36(8):943–950. doi:10.1177/02698811221082442
Vandeputte MM, Krotulski AJ, Walther D, et al. Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole 'nitazene' synthetic opioid. Arch Toxicol 2022;96(6):1845–1863. doi:10.1007/s00204-022-03276-4
Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997;54(1):49–55. doi:10.1001/archpsyc.1997.01830130055011
Viti L, Tartaglione L, Rizzi A, et al. A case of Hirata syndrome in pregnancy induced by alpha-lipoic acid: diagnosis and management. AACE Endocrinol Diabetes 2025;12(2):84-88. doi:10.1016/j.aed.2025.03.012
Vojtěchovský M, Hort V, Šafratová V. Influence of MAO inhibitors on psilocybine induced psychosis. Activitas Nervosa Superior 1968;10(3):278–279 (via Tap 2025).
Volak LP, Ghirmai S, Cashman JR, Court MH. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos 2008;36(8):1594–1605. doi:10.1124/dmd.108.020552
Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 1998;9:3897–3902. doi:10.1097/00001756-199812010-00024
Wolbach AB, Isbell H, Miner EJ. Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions. Psychopharmacologia 1962;3:1–14. doi:10.1007/BF00413101
Wu F, Wang Y, Mei Q, et al. UGTs-mediated metabolic interactions contribute to enhanced anti-inflammation activity of Jinhongtang. J Ethnopharmacol 2023;304:116016. doi:10.1016/j.jep.2022.116016
Xie W, Su F, Wang G, et al. Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis. Front Pharmacol 2022;13:1015045. doi:10.3389/fphar.2022.1015045
Zanda MT, Fadda P, Chiamulera C, Fratta W, Fattore L. Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findings. Behav Pharmacol 2016;27(6):489–496. doi:10.1097/FBP.0000000000000241
Zawilska JB, Kacela M, Adamowicz P. NBOMes — highly potent and toxic alternatives of LSD. Front Neurosci 2020;14:78. doi:10.3389/fnins.2020.00078
AgreementPsilodex

Before you use Psilodex

Check each box to continue.

Your searches, your list and the medications you look up stay in this browser. We can't see them. Privacy · Emergency: 911 · Mental health crisis: call or text 988 · Poison Control: 1-800-222-1222

Terms version 2026-10-25